<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516709</url>
  </required_header>
  <id_info>
    <org_study_id>CT003</org_study_id>
    <nct_id>NCT02516709</nct_id>
  </id_info>
  <brief_title>Linear Source Registry for Prostate Cancer</brief_title>
  <acronym>CaRePC</acronym>
  <official_title>CivaString Registry for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CivaTech Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CivaTech Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ongoing follow up for subjects implanted with the Linear Source String for prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry is being conducted to provide long term analysis on the use of the linear
      Civastring source for prostate cancer. Prospective data collection will record and
      demonstrate biochemical response rates. Long term side effects and adverse events will be
      monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Biochemical Response Rate (PSA)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effects (IPSS, IIEF, RFAS score)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Linear LDR Source</intervention_name>
    <description>The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients currently indicated for brachytherapy, implanted with the linear LDR source for
        prostate cancer with a life expectancy greater than 5 years
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Plans to remain in care of enrolling physician for 5 years

          -  &gt; 5 years life expectancy

          -  Signed informed consent

          -  Enrolled within 6 weeks of implant or within 365 days of prior implant

        Exclusion Criteria:

          -  Not willing or able to comply with protocol visit schedule
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristy Perez, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CivaTech Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carra Castagnero</last_name>
    <phone>919-314-5515</phone>
    <email>clinical@civatechoncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chicago Prostate Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60559</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Smalcuga</last_name>
      <phone>630-654-2515</phone>
      <email>jsmalcuga@chicagoprostatefoundation.org</email>
    </contact>
    <investigator>
      <last_name>Brian Moran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Researcch</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Sookhoo, MS</last_name>
      <phone>212-480-3333</phone>
      <email>sean@manhattanmedicalresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Betsy Moclair, RN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jed Kaminetsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours DePaul Medical Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Purrington, MSN</last_name>
      <phone>757-278-2171</phone>
      <email>Elizabeth_Purrington@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Bradley Prestidge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2015</study_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

